Articles related to ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

The introduction of lisdexamfetamine, a generic for Vyvanse, initially showed promise in increasing access to ADHD treatment. However, it too has fallen into shortage, highlighting the ongoing challenges in meeting patient demand.

The rise of telepsychiatry during the pandemic has increased ADHD diagnoses in adults, yet challenges remain in ensuring thorough evaluations and compliance with evolving prescribing regulations.

Recent research indicates an incremental risk of cardiomyopathy associated with extended stimulant use in ADHD treatment among young adults. Notably, this risk peaks at eight years of therapy, reinforcing the need for vigilant cardiovascular monitoring.

This study offers valuable insights into the safety of stimulant medication use during pregnancy, highlighting the need for nuanced patient counseling and consideration of individual risks and benefits in managing ADHD symptoms.

The recent recall of Zenzedi 30 mg tablets due to contamination stresses the importance of meticulous medication management and awareness of the broader challenges in ADHD treatment availability and safety.

Recent findings highlight a significant overlap between ADHD and ASD, particularly in symptomatology and diagnostic challenges. Understanding these nuances is crucial for accurate patient assessment and treatment.